TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27812798

Group type: EXPERIMENTAL
Intervention: Mobile app
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Web app
Number of subjects: 4
Study: 25880034

Group type: EXPERIMENTAL
Intervention: Aroma-acupressure
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Aromatherapy
Number of subjects: 186

Group type: COMPARATOR
Intervention: Control (routine care)
Number of subjects: 186
Study: 23993130

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400mg once daily
Number of subjects: 1156

Group type: COMPARATOR
Intervention: Ofloxacin 400mg twice daily plus Metronidazole 500mg twice daily
Number of subjects: 1156
Study: 21898711

Group type: EXPERIMENTAL
Intervention: Fast left repetitive transcranial magnetic stimulation (rTMS) at 10 Hz @ 120% of motor threshold (MT) over the left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Slow right rTMS at 1 Hz @ 120% MT over the right DLPFC
Number of subjects: 141
Study: 19376589

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 1.25 mg bevacizumab
Number of subjects: 42

Group type: COMPARATOR
Intervention: Cataract surgery only (control)
Number of subjects: 42
Study: 17326710

Group type: EXPERIMENTAL
Intervention: Hypoglycemia induced by insulin infusion to nadir levels of 2.2 mmol/l
Number of subjects: 32

Group type: COMPARATOR
Intervention: Euglycemia maintained (control)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Awakening during hypoglycemia
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Increases in epinephrine
Number of subjects: 32
Study: 15381895

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.5 mg/kg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 12364470

Group type: EXPERIMENTAL
Intervention: High-dose GH (0.05 mg/kg.d)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Low-dose GH (0.025 mg/kg.d)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: High-dose GH-IGFBP-3 generation test
Number of subjects: 198
Study: 9845100

Group type: EXPERIMENTAL
Intervention: Continuous hyperfractionated accelerated radiation therapy with mitomycin C (V‐CHART + MMC)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Continuous hyperfractionated accelerated radiation therapy (V‐CHART)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Conventional fractionation (CF)
Number of subjects: 188
Study: 7978438

Group type: EXPERIMENTAL
Intervention: Clonidine (transdermal 0.2 mg/d for 72 h + oral 0.3 mg 60‐90 min before surgery)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 2729850

Group type: EXPERIMENTAL
Intervention: Cloxacillin
Number of subjects: 42

Group type: COMPARATOR
Intervention: Nontreatment (Control)
Number of subjects: 42
Study: 31883356

Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (FCM)
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1100
Study: 27445067

Group type: EXPERIMENTAL
Intervention: HA‐trehalose (n = 52)
Number of subjects: 105

Group type: COMPARATOR
Intervention: HA (n = 53)
Number of subjects: 105
Study: 24246711

Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection (ICSI)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Conventional in vitro fertilization (IVF)
Number of subjects: 249
Study: 23290005

Group type: EXPERIMENTAL
Intervention: Hippotherapy (8-week program)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28
Study: 21703665

Group type: EXPERIMENTAL
Intervention: Diesel emission control law enforcement (April 2006 to December 2008)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pre-enforcement period (April 2003 to March 2006)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High traffic areas post-enforcement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Crude interrupted time-series analysis
Number of subjects: 0
Study: 17631296

Group type: EXPERIMENTAL
Intervention: Tesaglitazar (0.1, 0.25, 0.5, and 1mg) once daily for 12 weeks
Number of subjects: 390
Study: 16729760

Group type: EXPERIMENTAL
Intervention: Standard treatment + bioactive substances in formula CognoBlend (2 capsules twice a day for 5 weeks)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 66
Study: 15314590

Group type: EXPERIMENTAL
Intervention: Subtenons lidocaine injection (1 ml of 2% lidocaine)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group (no subtenons lidocaine injection)
Number of subjects: 111
Study: 11230794

Group type: EXPERIMENTAL
Intervention: Nuclear magnetic resonance (NMR) spectroscopy to determine HDL particle size and subclasses
Number of subjects: 918

Group type: EXPERIMENTAL
Intervention: Nuclear magnetic resonance (NMR) spectroscopy to determine HDL subclasses
Number of subjects: 918
Study: 9294492

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at a daily subcutaneous dose of 0.2 or 0.3 IU/kg for 2 years
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 21
Study: 8322989

Group type: EXPERIMENTAL
Intervention: 1 mg of diamorphine added to 4 ml of 0.5% bupivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: 4 ml of 0.5% bupivacaine alone
Number of subjects: 60
Study: 2422973

Group type: EXPERIMENTAL
Intervention: Case history (CH) combined with skin tests (ST)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: RAST (allergen-specific serum IgE)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Skin tests (ST) combined with either RAST or basophil histamine release (HR)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Basophil histamine release (HR) as a single analysis
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Various combinations of tests
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Altering the concentration of allergen
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Bronchial provocation tests (BPT)
Number of subjects: 26
Study: 29652275

Group type: EXPERIMENTAL
Intervention: Ketofol infusion (ketamine: propofol, 1mg: 3 mg in 20 ml syringe)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Dexmedetomidine infusion (200 μg in 20 ml normal saline)
Number of subjects: 50
Study: 27443361

Group type: EXPERIMENTAL
Intervention: Bone-anchored intermaxillary traction (BAIMT)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Removable mandibular retractor (RMR)
Number of subjects: 38
Study: 24418653

Group type: EXPERIMENTAL
Intervention: CB bibliotherapy
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: CB group
Number of subjects: 378

Group type: COMPARATOR
Intervention: Control condition (educational brochure)
Number of subjects: 378
Study: 22687642

Group type: EXPERIMENTAL
Intervention: Pioglitazone 15 mg/day for two months (PIO 15)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pioglitazone 15 mg/day for one month followed by 30 mg/day for an additional one month (PIO 30)
Number of subjects: 0
Study: 20138037

Group type: EXPERIMENTAL
Intervention: Active PES
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham PES (Control)
Number of subjects: 50
Study: 18477013

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation during pregnancy and lactation
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation in allergic mothers
Number of subjects: 171
Study: 15625255

Group type: EXPERIMENTAL
Intervention: Patient Controlled Inhalational Induction (PCI)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Vital Capacity Inhalational Induction (VCI)
Number of subjects: 124
Study: 12649050

Group type: EXPERIMENTAL
Intervention: Diet history interview
Number of subjects: 56

Group type: COMPARATOR
Intervention: Food record
Number of subjects: 56
Study: 10961590

Group type: EXPERIMENTAL
Intervention: Budesonide CIR 15 mg
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Budesonide CIR 9 mg
Number of subjects: 258

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 258
Study: 9200284

Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg, four times daily for 4 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: COMPARATOR
Intervention: Cisapride and Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 70
Study: 1487921

Group type: EXPERIMENTAL
Intervention: Stairobic stepping (SS) at 40 st/min
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Stairobic stepping (SS) at 60 st/min
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Stairobic stepping (SS) at 80 st/min
Number of subjects: 12

Group type: COMPARATOR
Intervention: Bench stepping (BS) at 20 st/min
Number of subjects: 12

Group type: COMPARATOR
Intervention: Bench stepping (BS) at 30 st/min
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Stairobic MET (SM) at two lowest SS rates
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Stairobic MET (SM) at highest SS rate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Physiologic cost of BS
Number of subjects: 12
Study: 3103572

Group type: EXPERIMENTAL
Intervention: 0.75 mg/kg of tissue plasminogen activator (rt‐PA)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 31658051

Group type: EXPERIMENTAL
Intervention: Intravenous omega-3 poly-unsaturated fatty acids (n-3 PUFAs)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 44
Study: 28940323

Group type: EXPERIMENTAL
Intervention: Fenwal Amicus
Number of subjects: 57

Group type: COMPARATOR
Intervention: Terumo BCT Spectra Optia
Number of subjects: 57
Study: 27843165

Group type: EXPERIMENTAL
Intervention: Neonatal mortality rate
Number of subjects: 149570

Group type: EXPERIMENTAL
Intervention: Mortality within 24 hours of birth
Number of subjects: 149570

Group type: EXPERIMENTAL
Intervention: Mortality within the first 6 hours
Number of subjects: 149570
Study: 24104513

Group type: EXPERIMENTAL
Intervention: Training programme for joint attention and imitation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 36
Study: 22542530

Group type: COMPARATOR
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day) / Ezetimibe (10 mg/day)
Number of subjects: 50
Study: 20087195

Group type: EXPERIMENTAL
Intervention: Once-nightly dosing (didanosine plus lamivudine with efavirenz)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Twice-daily dosing (combivir with efavirenz)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Once-nightly dosing
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: High initial concerns about HAART
Number of subjects: 87
Study: 18833174

Group type: EXPERIMENTAL
Intervention: Transcranial dynamic magnetic therapy (along with basic therapy)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Basic therapy
Number of subjects: 54
Study: 15921965

Group type: EXPERIMENTAL
Intervention: Niflumic acid quantitation using HPLC method with UV detection (288 nm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Niflumic acid levels in plasma samples
Number of subjects: 0
Study: 14695440

Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum strains supplementation
Number of subjects: 0
Study: 9640146

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide at 20 vpm
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide at 1 vpm
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide at 40 vpm
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide at 10 vpm
Number of subjects: 19
Study: 7660402

Group type: EXPERIMENTAL
Intervention: Elevated levels of lipoprotein(a) [Lp(a)]
Number of subjects: 885

Group type: COMPARATOR
Intervention: Hormone replacement therapy in women
Number of subjects: 885

Group type: EXPERIMENTAL
Intervention: Lp(a) as a predictor of carotid atherosclerosis
Number of subjects: 885

Group type: EXPERIMENTAL
Intervention: Fibrinogen and antithrombin III
Number of subjects: 885
Study: 2855516

Group type: EXPERIMENTAL
Intervention: Diet and smoking intervention
Number of subjects: 1232
Study: 29778980

Group type: EXPERIMENTAL
Intervention: Early AFO provision (at inclusion)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Delayed AFO provision (eight weeks later)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Early AFO provision
Number of subjects: 26

Group type: COMPARATOR
Intervention: Delayed AFO provision
Number of subjects: 26
Study: 26538105

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT) for 3 months starting at 12 months post-operation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no PFMT) starting at 15 months post-operation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT) for 3 months
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no PFMT)
Number of subjects: 12
Study: 25700806

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 400 mcg and umeclidinium (UMEC) 500 mcg administered in combination (FF/UMEC 100/125 mcg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Fluticasone furoate (FF) 100 mcg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Umeclidinium (UMEC) 125 mcg
Number of subjects: 18
Study: 22950541

Group type: EXPERIMENTAL
Intervention: Prescribed fluid equal to sweat loss (1.65 +/- 0.17 litres)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Ad libitum fluid (0.85 +/- 0.19 litres)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: No fluid
Number of subjects: 13
Study: 21885255

Group type: EXPERIMENTAL
Intervention: Cathodal transcranial direct current stimulation (tDCS) at 1 mA for 20 min
Number of subjects: 5

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 5
Study: 19542781

Group type: EXPERIMENTAL
Intervention: 200-m fast-walk test
Number of subjects: 30

Group type: COMPARATOR
Intervention: 6-min walk test
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cardiopulmonary exercise test
Number of subjects: 30
Study: 16415377

Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin per day
Number of subjects: 471

Group type: COMPARATOR
Intervention: 10 mg atorvastatin per day
Number of subjects: 471
Study: 15228801

Group type: EXPERIMENTAL
Intervention: Mental practice (MP) for mobility tasks
Number of subjects: 12
Study: 11331680

Group type: EXPERIMENTAL
Intervention: Maternal lead burden (measured in blood and bone)
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Maternal patella lead levels
Number of subjects: 329
Study: 9204729

Group type: EXPERIMENTAL
Intervention: Educational intervention by Umbanda healers on biomedical prevention of AIDS
Number of subjects: 126

Group type: COMPARATOR
Intervention: Untrained controls
Number of subjects: 126
Study: 8357774

Group type: EXPERIMENTAL
Intervention: Benazepril (10 or 20 mg once daily)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 3900590

Group type: EXPERIMENTAL
Intervention: Verapamil 80 mg every 8 hours for 5 days
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study: 29193822

Group type: EXPERIMENTAL
Intervention: Nidek AR‐360A autorefractometer
Number of subjects: 1238
Study: 26546376

Group type: EXPERIMENTAL
Intervention: C-arm intraoperative imaging during fracture reduction
Number of subjects: 50

Group type: COMPARATOR
Intervention: Post-surgery imaging for fracture reduction control
Number of subjects: 50
Study: 24579804

Group type: EXPERIMENTAL
Intervention: Dorsal onlay buccal mucosa graft (BMG) urethroplasty
Number of subjects: 37

Group type: COMPARATOR
Intervention: Dorsal onlay penile skin flap (PSF) urethroplasty
Number of subjects: 37
Study: 22656391

Group type: EXPERIMENTAL
Intervention: Alcohol-free baby wipe
Number of subjects: 280

Group type: COMPARATOR
Intervention: Cotton wool and water (usual care)
Number of subjects: 280
Study: 19558428

Group type: EXPERIMENTAL
Intervention: Fluconazole cream 0.5%
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Fluconazole cream 1%
Number of subjects: 162

Group type: COMPARATOR
Intervention: Flutrimazole cream 1%
Number of subjects: 162
Study: 17957184

Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg
Number of subjects: 19

Group type: COMPARATOR
Intervention: Atorvastatin 20 mg
Number of subjects: 19
Study: 17545266

Group type: EXPERIMENTAL
Intervention: Amalgam restorations
Number of subjects: 472

Group type: COMPARATOR
Intervention: Composite restorations
Number of subjects: 472
Study: 14722144

Group type: EXPERIMENTAL
Intervention: H pylori eradication treatment (2-week course of omeprazole 20 mg, amoxicillin and clavulanate potassium 750 mg, and metronidazole 400 mg, all twice daily, n = 817)
Number of subjects: 1630

Group type: COMPARATOR
Intervention: Placebo (n = 813)
Number of subjects: 1630

Group type: EXPERIMENTAL
Intervention: H pylori eradication treatment (n = 817)
Number of subjects: 1630
Study: 10714087

Group type: EXPERIMENTAL
Intervention: Gastrectomized patients
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 46
Study: 9181649

Group type: EXPERIMENTAL
Intervention: Loracarbef (200 mg twice daily for 10 days)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Phenoxymethylpenicillin (800/1000 mg twice daily for 10 days)
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Loracarbef
Number of subjects: 331

Group type: COMPARATOR
Intervention: Phenoxymethylpenicillin
Number of subjects: 331
Study: 1557934

Group type: EXPERIMENTAL
Intervention: SPf66 vaccine
Number of subjects: 399

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399
Study: 4077772

Group type: EXPERIMENTAL
Intervention: 5-nitroimidazole compounds (including satranidazole, ronidazole, S75 0400 A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other antiprotozoal drugs (berberine sulphate, paromomycin sulphate, erythromycin estolate, sulphasalazine)
Number of subjects: 0
Study: 31023329

Group type: EXPERIMENTAL
Intervention: Physical activity promoting intervention (12-week program including education, social support, group discussion, follow-up calls, printed information)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Physical activity promoting intervention
Number of subjects: 40
Study: 28824193

Group type: EXPERIMENTAL
Intervention: 50 mg diclofenac suppository plus 5 mg isosorbide dinitrate sublingual tablet
Number of subjects: 900

Group type: COMPARATOR
Intervention: 50 mg diclofenac suppository alone
Number of subjects: 900
Study: 25770814

Group type: EXPERIMENTAL
Intervention: Aprepitant plus ondansetron on day 1, followed by aprepitant on days 2 and 3 (125 mg for ages 12-17 years; 3.0 mg/kg up to 125 mg for ages 6 months to <12 years; 80 mg for ages 12-17 years; 2.0 mg/kg up to 80 mg for ages 6 months to <12 years)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Placebo plus ondansetron on day 1, followed by placebo on days 2 and 3
Number of subjects: 307
Study: 23584582

Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 1709

Group type: COMPARATOR
Intervention: PCV7
Number of subjects: 1709
Study: 21591943

Group type: EXPERIMENTAL
Intervention: Alemtuzumab (30 mg, one dose)
Number of subjects: 474

Group type: COMPARATOR
Intervention: Rabbit antithymocyte globulin (6 mg/kg over 4 days)
Number of subjects: 474

Group type: COMPARATOR
Intervention: Basiliximab (40 mg over 4 days)
Number of subjects: 474
Study: 19701033

Group type: EXPERIMENTAL
Intervention: 2% lidocaine hydrochloride jelly
Number of subjects: 137

Group type: COMPARATOR
Intervention: Plain aqueous gel
Number of subjects: 137
Study: 16758747

Group type: EXPERIMENTAL
Intervention: Pegylated interferon
Number of subjects: 0
Study: 12635973

Group type: EXPERIMENTAL
Intervention: Colouring in a drawing of a nice figure
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Colouring in a drawing of a nasty figure
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Colouring in a drawing of a neutrally characterised figure
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Colouring in a drawing of a neutral figure
Number of subjects: 330
Study: 10874260

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy for myocardial infarction
Number of subjects: 0
Study: 9114992

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg once daily
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Cetirizine 5 mg once daily
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study: 8261302

Group type: EXPERIMENTAL
Intervention: Flexible cystoscopy
Number of subjects: 53

Group type: COMPARATOR
Intervention: Rod-lens cystoscopy
Number of subjects: 53
Study: 4029404

Group type: EXPERIMENTAL
Intervention: Iridium implantation
Number of subjects: 47

Group type: COMPARATOR
Intervention: External boost
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Periareolar incision
Number of subjects: 47

Group type: COMPARATOR
Intervention: Other incisions
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Small and medium breasts
Number of subjects: 47

Group type: COMPARATOR
Intervention: Large breasts
Number of subjects: 47
Study: 30329030

Group type: EXPERIMENTAL
Intervention: Measles vaccination in the presence of maternal measles antibodies
Number of subjects: 0
Study: 29949429

Group type: EXPERIMENTAL
Intervention: Cabergoline (3 mg/week)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg twice daily)
Number of subjects: 44
Study: 27114605

Group type: EXPERIMENTAL
Intervention: Cetuximab monotherapy (400 mg/m2 loading dose and then 250 mg/m2 once per week)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Cetuximab plus irinotecan (cetuximab 400 mg/m2 loading dose and then 250 mg/m2 once per week with irinotecan 180 mg/m2 once every 2 weeks)
Number of subjects: 51
Study: 25345071

Group type: EXPERIMENTAL
Intervention: Unspecific resistance training with dumbbells (12 repetition maximum squats)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Specific resistance training with weighted belts (6% of body mass)
Number of subjects: 57
Study: 22404184

Group type: EXPERIMENTAL
Intervention: Baclofen (40 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 20162342

Group type: EXPERIMENTAL
Intervention: Valid study
Number of subjects: 223

Group type: COMPARATOR
Intervention: Missing control group
Number of subjects: 223

Group type: COMPARATOR
Intervention: Confound
Number of subjects: 223

Group type: COMPARATOR
Intervention: Experimenter bias
Number of subjects: 223